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1- University of Texas- School of Medicine
2- 2- Valley Baptist Neuroscience Institute, Department of Psychiatry and Neurology,
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Object. Systemic heparinization perioperatively is standard during ruptured aneurysm
coiling. However, current guidelines do not address whether different timing protocols affects
perioperative complications. This study evaluates ruptured aneurysms treated with coiling and
whether differences in perioperative complication rates exist with two different treatment
protocols.
Methods. 242 patients were retrospectively identified and divided based on timing of
systemic heparin distribution intraoperatively. Demographic data and clinical data were collected
and compared. Perioperative complications in both treatment arms were analyzed and risk of rerupture and stroke compared.
Results. 93 patients were treated with systemic heparinization at beginning of the
procedure (Protocol 1) and 149 patients were treated with systemic heparinization at the
beginning and after deployment of the first coil (Protocol 2). 8 (3.31%) total patients, with 1
(1.08%) patient in Protocol 1 and 7 (4.70%) patients in Protocol 2 had perioperative re-rupture
events. 6 (2.48%) of total patients, with 2 (2.15%) patients in Protocol 1 and 4 (2.68%) patients
in Protocol 2 experienced perioperative stroke event.
Conclusions. Difference in timing of systemic heparinization did not appear to increase
the frequency of perioperative complications.
Introduction:
Endovascular embolization of cerebral aneurysms has been widely associated with both
low morbidity and mortality rates, whether ruptured or unruptured. Like many endovascular
procedures, embolization is associated with a risk of perioperative thromboembolic, ischemic, as
well as rebleeding complications, and these complications remain the most significant factors of
poor outcomes.
Several studies have been done ascertaining other interventions that reduce
thromboembolism risk without increasing hemorrhagic complications. Other studies have
focused on assessing incidence of perioperative complications due to factors such as type of
aneurysm treatment modality, clinical characteristics and risk factors of patients, preoperative
prevention and postoperative events.
Current guidelines recommend perioperative systemic administration of heparin to reduce
intraprocedural thromboembolism risk and standard dosing recommendations exist. However,
there is a wide variation in protocols regarding timing of distribution during embolization
procedures. Thus far, a comparative analysis has not been performed to determine differences in
timing of distribution of systemic heparinization perioperatively and its effect on ischemic and
hemorrhagic complication rates.
We performed this analysis to evaluate the differences, if any, on the frequency of
perioperative complications in relation to the timing of intraprocedural distribution of systemic

heparin, particularly looking at if earlier administration increases bleeding diathesis and if later
administration increases ischemic events.
Materials and Methods:
We retrospectively identified and reviewed prospectively collected medical records of all
patients with a primary diagnosis of subarachnoid hemorrhage due to ruptured aneurysm who
were treated with detachable coils at a high-volume, single center endovascular site from July
2012 to September 2020.
Patients were brought into the angiography suite and placed in supine position. Arteries
are accessed with 19-gauge needle which is exchanged with a 5-8 French Terumo sheath over a
wire. Under fluoroscopic guidance, 088 Neuron MAX or Balt Ballast guide catheters are
advanced. Pressured saline bags are connected to guide catheters and sheath at 2000 U/L. Once
parent artery is selected, Scepter XC 4x11 balloon microcatheter is advanced over a 042
Synchro-2 microwire to selectively catheterize the artery. Then a Headway 17 or sL10
microcatheter is advanced over the Synchro-2 microwire to selectively catheterize the aneurysm
using Hydrogel coils. During the procedure, patients were either treated with a single dose of 35
U/kg systemic heparin at beginning of the procedure or dosing of 35 U/kg at beginning of
procedure and another 35 U/kg after deployment of first coil.
Selection criteria for endovascular treatment were based on imaging and clinical criteria.
Baseline demographic data included age and sex. Baseline clinical data included Hunt and Hess
Scale (H/H), Modified Fisher Grade (MFg), and aneurysm size (length and neck width). Clinical
outcomes included intraoperative complication rates, specifically re-rupture and stroke.
Statistical Analysis:
Overall, 242 patients were identified meeting the inclusion criteria and were subdivided into 2
groups based on the timing of distribution of systemic heparin intraoperatively, Protocol 1 and 2.
Protocol 1 consisted of patients receiving 35 U/kg of systemic heparin at the beginning of the
procedure (n=93) while Protocol 2 consisted of patients receiving 35 U/kg at the beginning of
procedure and after deployment of the first coil (n=149).
All data were descriptively presented using mean ± standard error (SE) for continuous data and
frequencies for categorical data. Comparison between continuous data was assessed using oneway ANOVA and chi-square test or Fisher’s Exact Test for categorical variables. A p-value of
<0.05 was considered to be significant. All statistical analyses were performed using R software
package.
Results:
Of the 242 patients who underwent coil embolization of ruptured aneurysms, 93 (38.4%)
treated under Protocol 1 and 149 (61.6%) treated under Protocol 2. Mean age (± SE) of all
patients was 57.66 ± 1.01 with no statistical difference between protocol arms (p-value = 0.78),
72.31% (n=175) women. Total complication rate was 5.79% (n=14), with 3.31% (n=8) having
intraprocedural re-rupture of aneurysm and 2.48% (n=6) having intraprocedural ischemic event.
Demographic characteristics of the patient population studied according to protocol strata can be
seen in Table 1.

Univariate analysis of predictive variables and risk factors measured—Hunt and Hess
Scale, Modified Fisher Grade, and aneurysm size—are shown in Table 1. Median Hunt and Hess
Scale was 2 overall, 3 for Protocol 1, and 2 for Protocol 2. Frequency of patients with baseline
Hunt and Hess Scale of 1 was greater in Protocol 1 than Protocol 2 (n=29 and n=18, respectively,
p=0.00039) and baseline Hunt and Hess Scale of 2 was greater in Protocol 2 than Protocol 1
(n=68 and n=15, respectively, p=0.000002). Hunt and Hess Scales 3, 4, and 5 showed no
significant difference between protocol strata (p=0.54, p=0.08, p=0.32, respectively). Median
Modified Fisher Grade was 3 overall, 4 for Protocol 1, and 3 for Protocol 2. With respect to
Modified Fisher Grade, both protocols showed no significant difference at grades 1 and 2
(p=0.16, p=0.22, respectively). However, there was a significant difference in patients graded at
3 and 4, with Protocol 2 showing a greater degree of patients graded at 3 than Protocol 1 (n=101
vs. n=37, p=0.00003, respectively) and Protocol 1 showing a greater degree than Protocol 2
graded at 4 (n=48, n=35, p=0.00001, respectively). The mean ± SE differences of aneurysm
length for Protocol 1 vs. 2 (6.17 ± 0.38 vs. 6.20 ± 0.26, respectively) and width (4.78 ± 0.33 vs.
4.68 ± 0.20) did not show any significant differences (p=0.93, p=0.80).
Frequency of intraoperative re-rupture of aneurysm was recorded to be 1.08% (n=1) for
Protocol 1 and 4.70% (n=7) for Protocol 2 (p=0.18) and frequency of intraoperative stroke was
recorded to be 2.15% (n=2) for Protocol 1 and 2.68% (n=4) for Protocol 2 (p=1.00), failing to
show any significant different between protocols for either of the endpoints.
Table 1: Characteristics of patients and comparison of perioperative complications
within Protocol cohorts
35 U/kg At
35 U/kg At
Start and
All Patients
Start
After First
P-Value
n= 242
n= 93
Coil
n= 149
Age (mean ± SE)
57.66 ± 1.01
57.30 ± 1.70
57.89 ± 1.25
0.78
Sex
Male (%)
67 (27.69)
28 (30.11)
39 (26.17)
0.56
Female (%) 175 (72.31)
65 (69.89)
110 (73.83)
Hunt and Hess
1 (%)
2 (%)
3 (%)
4 (%)
5 (%)

47 (19.42)
83 (34.30)
59 (24.38)
43 (17.77)
10 (4.13)

Median
2
Modified Fisher Grade
1 (%)
9 (3.72)

29 (31.18)
15 (16.13)
25 (26.88)
22 (23.66)
2 (2.15)

18 (12.08)
68 (45.64)
34 (22.82)
21 (14.09)
8 (5.37)

3

2

1 (1.08)

8 (5.37)

0.00039
0.000002
0.54
0.08
0.32

0.16

2 (%)
3 (%)
4 (%)

12 (4.96)
138 (57.02)
83 (34.30)

7 (7.53)
37 (39.78)
48 (51.61)

Median
3
4
Aneurysm Size (mean ± SEM)
Length (mm) 6.19 ± 0.22
6.17 ± 0.38
Width (mm) 4.73 ± 0.18
4.78 ± 0.33
Perioperative Complications (%)
Re-rupture (%)
8 (3.31)
1 (1.08)
Stroke (%)
6 (2.48)
2 (2.15)

5 (3.36)
101 (67.79)
35 (23.49)

0.22
0.00003
0.00001

3
6.20 ± 0.26
4.68 ± 0.20

0.93
0.8

7 (4.70)
4 (2.68)

0.18
1.00

Discussion:
Systemic distribution of heparin during endovascular procedures has been shown to
decrease the incidence of intraoperative complications, however standard guidelines as to timing
of this distribution and its effect on intraoperative complications has not been studied thus far.
The goal for this study was to compare whether differences in timing of distribution of systemic
heparin during ruptured aneurysm coiling would cause differences in intraoperative rebleeding
and ischemic events, specifically whether patients receiving earlier heparinization were at
increased risk for aneurysm rebleeding and whether later distribution would increase ischemic
events. This study has shown that patients undergoing systemic heparinization at the start of
procedure vs. after first coil has been dispensed when treating ruptured intracranial aneurysm has
no difference in effect on perioperative complication rate, whether it be bleeding or ischemic
events.
Despite some significant difference between predictive factors, particularly Hunt and
Hess scoring and Modified Fisher Grade, and similar baseline demographics, the outcome in
perioperative complication rates do not vary significantly between protocol arms and are in line
with rates found in other studies. Ries et al, performing a study comparing intraprocedural
distribution of system heparin vs heparin + acetylsalicylic acid, found that complication rates for
thromboembolic events ranged from 2.4%-5.2% while frequency for aneurysm rebleeding
ranged from 2.3%-4.3% (n=261). Similarly, a meta-analysis by the Ontario Medical Advisory
Secretariat found aneurysm coiling was associated with intraoperative thromboembolic events
ranging from 2.5%-14.5% and re-rupture rates ranging from 2.3%-4.7%. Pierot et al, in a
multicenter study of intraoperative complication rates when comparing coiling and balloonassisted coiling, thromboembolic rate of 10.4% and re-rupture rate of 3.1% were observed
(N=1088).
For the past two decades, significant research has been undertaken towards improving
complication rates of ruptured aneurysm treatment. These studies have looked at different
treatment modalities, preprocedural, intraprocedural, and postprocedural interventions, as well as
clinical and demographic factors to assess risk. However, standard of care for intraoperative
anticoagulation with systemic heparin has remained the same. Factors associated with
intraoperative coagulation parameters involving systemic heparinization remain an unaddressed
area of study, potentially impeding efforts at understanding the full scope of intraoperative
factors contributing to complication rates. Furthermore, the wide variability in protocols among

facilities and between physicians at these facilities necessitates the assessment these parameters
in order to potentially standardize treatment protocols to reduce intraoperative complication rates
and, thus, reduce morbidity and mortality among patients.
Limitations:
The most important limitation in this study is its retrospective nature and single center
study. This diminishes the ability to establish subgroups among patients and assess for endpoints
such as preoperative risk factors that might contribute to intraoperative complications. This also
contributes to the ubiquity of our finding due to the limited assessment of different timing of
distribution protocols and their effect on complication rate. Further studies are indicated to
increase power to better detect subgroup differences and assessing the ubiquity of these results.
Large multicenter prospective studies would be necessary to corroborate these results.
Conclusion:
Our study suggests that timing of distribution of systemic heparin intraoperatively during coiling
of ruptured aneurysm has no significant event on complication rates, specifically rebleeding and
thromboembolic events. This area remains relatively understudied and warrants further research
to establish whether timing of distribution could warrant reassessment of guidelines in
periprocedural systemic heparin protocols.
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